##
##
|The Trustees|The Trustees|have made the following
professional
appointments:|have made the following
professional
appointments:|||||||
|---|---|---|---|---|---|---|---|---|---|
|Solicitor:|||H Montlake
8c Co, 198 High Street, llford, Essex IG1 1LX|||||||
|Auditor:|||Kreston Reeves, Montague
Place, Quayside,
Chatham
Maritime,||Chatham,|||ME4||
||||4QU|||||||
|Bankers:|||CAF Bank Limited, 25 Kings
Hill Avenue,|Kings Hill, West Mailing,|Kent ME194JQ|||||
||||CCLA Investment
Management
Limited,|80Cheapside,
London|EC2V 6DZ|||||
||||Virgin Money, Jubilee House, Gosforth,|Newcastle
upon Tyne, NE3||4PL||||
||||The Charity Bank Limited, Fosse House,|182 High Street, Tonbridge,||TN9 1BE||||
||||Nationwide
Building Society, Nationwide|House, Pipers Way, Swindon,|||SN38 1NW|||
|Stockbrokers:|||Quilter Cheviot Investment
Management,|Senator House, 85 Queen Victoria St,||||||
||||London
EC4V 4AB|||||||
|Insurance|Brokers:||Insurance
Services (Surrey) Ltd, PO Box|1533,Waking,
GU22 2RY||||||
||||Secondsight,
Foster Denovo Group, 2 Hamm Moor Lane, Weybridge,|||Surrey||KT15|2SA|
|The following||key senior|members
of staff are responsible
for the day-to-day
activities||of|the|charity||who|
|together|with|the Trustees|form the key management
personnel
of|the charity:||||||
|Dr Marisa|Mason||Chief Executive
8~ Company
Secretary|||||||
|Dr Neil Smith|||Clinical Researcher 5 Deputy Chief Executive|||||||
##
##
##
##
|Association
ofAnaesthetists|Association
ofAnaesthetists|||Royal College of Ophthalmologists|Royal College of Ophthalmologists|
|---|---|---|---|---|---|
|Dr M Nathanson
—demitted||5 November|2020|Vacancy||
|Dr W Fawcett —appointed|5|November|2020|||
|Association
ofSurgeons ofGreat Britain|||and Ireland|Royal College of Paediatrics|and Child Health|
|Mr M Lansdown||||Drl Doughty||
|Royal College of Emergency||Medicine||Royal College of Physicians|of London|
|Dr A Boyle||||Dr M Kumwenda,
Dr H Skene and Dr A Gibson||
|Faculty of Dental Surgery||||Royal College of Physicians|and Surgeons of Glasgow|
|MrJ Dhanda||||Dr M McKirdy||
|Faculty of Intensive
Care|Medicine|||Royal College of Physicians|of Edinburgh|
|Dr J Butler||||Dr J MacLeod||
|Lay Representatives||||Royal College of Psychiatrists||
|Mr S Barasi —demitted
9|July 2020|||Dr J Carlile —demitted
28January 2021||
|Royal College ofAnaesthetists||||Royal College of Radiologists||
|Dr CCarey and Dr K Ramchandaran||||Prof R McWilliams||
|Royal College ofGeneral|Practitioners|||Royal College of Pathologists||
|Vacancy||||Dr L Igali||
|Royal College of Nursing||||Royal College ofSurgeons of Edinburgh||
|Dr N Ashby||||Miss A Paisley||
|Royal College ofObstetricians||and Gynaecologists||Royal College ofSurgeons of England||
|Dr T Hillard||||Miss SVig||
|Eleven consultants|had|been on secondment|to NCEPOD as Clinical Co-ordinators|between|1April 2020 and 31|
|---|---|---|---|---|---|
|March 2021, committing||to between
one and|two sessions per week,|||
|Dr M Docherty||Liaison Psychiatry||||
|Dr A Goodwin||Anaesthesia
and Critical Care||||
|Dr M Juniper||Respiratory
Medicine||||
|Dr K Malbon||Paediatrics||||
|Dr S McPherson||Radiology||||
|Dr A Michalski||Paediatric Oncology||||
|Mr M Sinclair||General Surgery||||
|Dr V Srivastava||Acute Medicine||||
|Dr A Tavare||General
Practice||||
|Dr K Wilkinson||Paediatric Anaesthesia||||
|Mr J Abercrombie||Surgery||||
##
##
##
##
##
##
##
##
##
##
##
##
##
|1.|Form the|Study Advisory|Group (SAG)|6.Test data collection methods|11.Data analysis|
|---|---|---|---|---|---|
|2.|Write the|protocol||7, Meet with the SAG for a second time|12.Write the report|
|3,|Design the questionnaires|||8. Final protocol to Steering Group and HQIP|13.Design the report|
|4.|Advertise|the study||9.Start data collection|14.Publish the report|
|5.|Advertise|for Reviewers||10.Run Reviewer meetings||
##
##
##
##
##
##
##
##
##
##
|Area ofstudy:||||Milestone reached:|
|---|---|---|---|---|
|Dysphagia
in Parkinson's||Disease||Report being written|
|Physical healthcare|in mental||health hospitals|Data being collected|
|Epilepsy||||Data being collected|
|Community
acquired|pneumonia|||Study being developed|
|Crohn's disease||||Study being developed|
|Transition
between|child|and|adult healthcare|Study being developed|
|Endornetriosis||||Study being developed|
|End of life care||||Study being developed|
|Testicular torsion||||Study being developed|
|Natural
deaths
in prison||||Study being developed|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||Total|Total|
|---|---|---|---|---|---|
||||Notes|2021|2020|
|||||f|f|
|INCOME FROM:||||||
|Donations||||12,000|132,300|
|Charitable
activities||||1,154,353|1,216,461|
|Investments||||10,303|18,139|
|TOTAL INCOME||||1,176,656|1,366,900|
|EXPENDITURE ON:||||||
|Charitable
activities||||972,248|1,278,134|
|TOTAL EXPENDITURE||||972,248|1,278,134|
|Net gain/(loss)
on|investments|||34,820|(53,061)|
|NET INCOME||||239,228|35,705|
|NET MOVEMENT|IN FUNDS|||239,229|35,705|
|RECONCILIATION|OF FUNDS|||||
|Fund balances
brought||forward||||
|at 1April 2020||||1,276,343|1,240,638|
|FUND BALANCES|CARRIED FORWARD|||||
|AT31MARCH 2021||||1,515,571|1,276,343|
|||Notes|2021|2020|
|---|---|---|---|---|
||||f|f|
|FIXED ASSETS|||||
|Tangible assets|||3,292|7,489|
|Investments|||212,538|151,957|
||||215,830|159,446|
|CURRENT ASSETS|||||
|Debtors|||355,757|361,396|
|Cash at bank and in|hand||1,091,609|770,598|
||||1,447,366|1,131,994|
|LIABILITIES|||||
|Creditors: Amounts|falling due within one year|10|{147,625)|(15,097)|
|NET CURRENT ASSETS|||1,299,741|1,116,897|
|TOTAL ASSETS LESS|CURRENT LIABILITIES||||
|& NET ASSETS|||1,515,571|1,276,343|
|THE FUNDS OF THE|CHARITY||||
|Unrestricted
income|funds||||
|General
Fund|||1,495,571|1,256,343|
|Designated
Premises|Fund||20,000|20,000|
|TOTAL CHARITY FUNDS|||1,515,571|1,276,343|
|||||Notes|2021|2020|
|---|---|---|---|---|---|---|
||||||f|f|
|Cash flows from operating|activities||||||
|Net cash provided
by operating||activities||13|338,206|122,131|
|Cash flows from investing|activities||||||
|Interest from investments|||||10,303|18,139|
|Purchase oftangible
fixed|assets||||(1,737)|(6,634)|
|Receipts from sale of investments|||||174,875|38,055|
|Purchase ofinvestments|||||(200,637)|(28,125)|
|Net cash (outflow) inflow|from|investing|activities||(17,196)|21,415|
|Increase (decrease)
in cash for the year|||||321,011|143,546|
|Cash brought
forward|||||770,598|627,052|
|Cash carried forward|||||||
||||||1,091,609|770,598|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||Total|Total|
|---|---|---|---|---|
||||2021|2020|
||||f|f|
|DONATIONS:|||||
|Donated services|||12,000|132,300|
||||12,000|132,300|
|INCOME FROM CHARITABLE ACTIVITIES —DESIGNING AND RUNNING|||CONFIDENTIAL SURVEY||
|Healthcare
Quality|Improvement||1,091,234|1,178,086|
|Partnership
(HQIP)|||||
|Private hospitals|||49,800|32,050|
|Conference,
exhibition||and other|||
|income sources|||13,319|6,325|
||||1,154,353|1,216,461|
|INVESTMENT INCOME|||||
|Dividends|||8,161|13,907|
|Bank interest receivable||on|||
|short term cash deposits|||2,142|4,232|
||||10,303|18,139|
|||||Total|Total|
|---|---|---|---|---|---|
|||||2021|2020|
|||||E|E|
|Support costs (note 5)||||244,142|290,704|
|Direct staff costs (note 6)||||515,358|588,651|
|Other direct expenditure:||||||
|Staff healthcare,
training,|and recruitment|||1,441|385|
|Clinical co-ordinators
secondments||||177,881|136,244|
|Clinical reviewers
(donated|services)|||12,000|132,300|
|Clinical co-ordinators,
reviewers,||and||||
|staff expenses||||6,508|60,566|
|Consultancy||||2,009|388|
|Temporary
staff costs|||||427|
|Conference,
exhibition,
and meetings||||||
|expenses||||(2,325)|10,703|
|Operating
lease rentals:||||||
|Plant and machinery||||5,666|5,666|
|Other printing
and report|production||costs|5,536|35,277|
|Postage and distribution||||4,032|5,346|
|Cardiff University —Child Health project|||||11,477|
|||||972,248|1,278,134|
||||Support|Governance|Total|Total|
|---|---|---|---|---|---|---|
||||costs|costs|2021|2020|
||||f|f|f|f|
|5.|SUPPORT AND GOVERNANCE|COSTS|||||
||Staff costs (note 6)|||691|691|1,490|
||Other expenditure:||||||
||Operating
lease rentals:||||||
||Land and buildings||136,747||136,747|145,620|
||Other premises costs||15,854||15,854|20,810|
||Auditors'
remuneration:||||||
||Audit fees|||10,288|10,288|10,000|
||Bookkeeping
and payroll costs||10,920|166|11,086|26,217|
||Public relations||447|7|454||
||Computer
expenses||30,660|467|31,127|30,111|
||Insurance||17,370|265|17,635|17,077|
||Sundry expenses||4,183|64|4,247|13,063|
||Telephone||4,468|68|4,536|2,832|
||Office costs||5,319|81|5,400|10,877|
||Steering Group expenses|||||3,837|
||Trustee expenses|||||3,042|
||Depreciation
—owned assets||5,849||5,934|5,640|
||Bank charges||143||143|88|
||||231,960|12,181|244,142|290,704|
##
|EAR COMPARATIVE||||||
|---|---|---|---|---|---|
|||Support|Governance|Total|Total|
|||costs|costs|2020|2019|
|||f|E|f|E|
|SUPPORT AND GOVERNANCE|COSTS|||||
|Staff costs (note 6)|||1,490|1,490|1,462|
|Other expenditure:||||||
|Operating
lease rentals:||||||
|Land and buildings||145,620||145,620|113,972|
|Other premises costs||20,810||20,810|16,919|
|Auditors'
remuneration:||||||
|Audit fees|||10,000|10,000|10,668|
|Bookkeeping
and payroll costs||26,138|79|26,217|27,375|
|Computer
expenses||30,021|90|30,111|24,159|
|Insurance||17,026|51|17,077|16,186|
|Sundry expenses||13,024|39|13,063|9,396|
|Telephone||2,824|8|2,832|4,087|
|Office costs||10,844|33|10,877|11,761|
|Steering Group||3,837||3,837|2,930|
|Trustee expenses|||3,042|3,042|2,576|
|Depreciation
—owned assets||5,623|17|5,640|5,237|
|Bank charges||88||88|88|
|||275,855|14,849|290,704|246,816|
|||||||2021|2020|
|---|---|---|---|---|---|---|---|
|6.|STAFF COSTS|||||||
|||||||No.|No.|
||The average monthly|number of persons employed|||by|||
||NCEPOD during the year||(excluding Trustees) was:|||||
||Designing
and running|of confidential||surveys||14|14|
||Staff costs for the above||persons:|||||
||Wages and salaries|||||434,049|492,875|
||Social security costs|||||38,975|50,210|
||Pension costs|||||43,025|47,055|
|||||||516,049|590,141|
||Staff costs are allocated||in the financial|statements,|as follows:|||
||Designing
and running|ofconfidential||surveys —unrestricted||515,358|588,651|
||Governance
costs|||||691|1,490|
|||||||516,049|590,141|
##
|||||Computer|Fixtures &||
|---|---|---|---|---|---|---|
|||||equipment|fittings|Total|
|||||E|f|E|
|Cost:|||||||
|1April 2020||||49,303|15,033|64,336|
|Additions||||1,737||1,737|
|Disposals||||(20,689)||(20,689)|
|31March|2021|||30,351|15,033|45,384|
|Depreciation:|||||||
|1April 2020||||42,361|14,486|56,847|
|Charge
in|the year|||5,536|398|5,934|
|Depreciation
on disposal||||(20,689)||(20,689)|
|31March|2021|||27,208|14,884|42,092|
|Net book|value:||||||
|31March|2021|||3,143|149|3,292|
|31March|2020|||6,942|547|7,489|
||||||2021|2020|
|INVESTMENTS|||||||
|Listed investments:|||||||
|Opening
balance at 1April|||||151,957|214,903|
|Additions|at cost||||200,637|39,997|
|(inc cash|account movement)|||||(11,872)|
|Disposals|||||(174,875)|(38,010)|
|Realised gains/losses||in|investments||22,918||
|Unrealised|gains/losses||on investments||11,902|(53,061)|
|Market value at 31March|||||212,538|151,957|
##
|||||||2021|2020|
|---|---|---|---|---|---|---|---|
||Analysis ofinvestment
holdings|||||||
||Invesco Perpetual|Enhanced|ln|Ld|Ord (IPE)||44,412|
||Balfour Beatty curn cnv pref||(BBYB)||||33,828|
||CQS New City High|Yield Fund||Ltd|Ord Npv (NCYF)||27,730|
||QC Global income|and Growth||Fund||212,538|43,774|
||Cash||||||2 213|
||Market value at 31March|||||212,538|151,957|
||DEBTORS|||||||
||Amounts
failing due within||one year:|||||
||Trade debtors|||||287,351|292,841|
||Other debtors|||||25,645|28,050|
||Prep ayments|||||42,761|40,505|
|||||||355,757|361,396|
|10.|CREDITORS|||||||
||Amounts
falling due within||one year:|||||
||Trade creditors|||||35,268|2,008|
||Accruals and deferred
income|||||112,357|13,089|
|||||||147,625|15,097|
||Deferred income|||||||
||Deferred income at 1April||2020|||||
||Resources deferred
during||the|year||88,000||
||Amounts
released|from previous|||years|||
|||||||88,000||
##
##
||||1April|Income|Expenditure|Gain on|31March|
|---|---|---|---|---|---|---|---|
||||2020|||Investment|2021|
||||f|f|f|f|f|
|Unrestricted||income|funds:|||||
|General|Fund||1,256,343|1,176,656|(972,247)|34,820|1,495,571|
|Designated||Premises|20,000||||20,000|
|Fund||||||||
||||1,276,343|1,176,656|(972,247)|34,820|1,515,571|
##
|||||1|April|Income|Expenditure|Loss on|31March|
|---|---|---|---|---|---|---|---|---|---|
||||||2019|||Investment|2020|
||||||f|||f|f|
|Unrestricted||income|funds:|||||||
|General|Fund|||1,220,638||1,366,900|(1,278,134)|(53,061)|1,256,343|
|Designated||Premises||20,000|||||20,000|
|Fund||||||||||
|||||1,240,638||1,366,900|(1,278,314)|(53,061)|1,276,343|
|NALYSIS|OF|NET ASSETS BETWEEN FUNDS||||||||
|||||||Fixed asset|Tangible fixed|Net current|Total|
|||||||investments|assets|assets||
|||||||f|f|f||
|Unrestricted||income|funds:|||||||
|General|Fund|||||212,538|3,292|1,279,741|1,495,571|
|Designated||Premises|Fund|||||20,000|20,000|
|NET ASSETS||AT 31MARCH||2020||212,538|3,292|1,299,741|1,515,571|
|||||||Fixed asset|Tangible fixed|Net current|Total|
|||||||investments|assets|assets||
|||||||f|f|f||
|Unrestricted||income|funds:|||||||
|General|Fund|||||151,957|7,489|1,116,897|1,276,343|
|Designated||Premises|Fund|||||20,000|20,000|
|NET ASSETS||AT31MARCH||2019||151,957|7,489|1,136,897|1,296,343|
##
##
||||2021|2020|
|---|---|---|---|---|
||||f|f|
|Net income for the|year||239,228|35,705|
|Depreciation
(note|7)||5,934|5,640|
|(Gains)/loss
on investments|||(34,820)|53,061|
|Interest from investment|||(10,303)|(18,139)|
|Decrease (Increase)|in debtors||5,639|51,471|
|(Decrease) increase|in creditors||132,528|(5,607)|
|Net cash from oper|ating|activities|338,206|122,131|
##
|||2021|||2020||
|---|---|---|---|---|---|---|
|||Land 5 Building|Equipment|Land 8 Building||Equipment|
||Within 1year|f142,000|f5,606|f142,000||f5,608|
||Within 2-5 years|f71,000|f1,402|f213,000||f7,008|
||Total|f213,000|f7,008|f355,000||f12,616|
|15.|NET DEBT RECONCILIATION||||||
|||At 1|April 2020|Cash flows|At 31March 2021||
||||f||||
||Cash at bank and in hand||770,598|321,011||1,091,609|
||Debt||||||
||Total||770,598|321,011||1,091,609|
|16.|ANALYSIS OF CASH AND CASH EQUIVALENTS||||||
||||2021|2020|||
||||f|f|||
||Cash in hand||1,091,609|1,091,609|||
||Total cash and cash equivalents||1,091,609|1,091,609|||
##
##